study

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty and Adductoplasty Outcomes at the 2025 ACFAS Annual Scientific ConferenceTreace Announces Clinical Study Data Demonstrating Positive Lapiplasty and Adductoplasty Outcomes at the 2025 ACFAS Annual Scientific Conference

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty and Adductoplasty Outcomes at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical…

19 hours ago
Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United StatesSupira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

LOS GATOS, Calif., March 26, 2025 /PRNewswire/ -- Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful…

3 days ago
New Study Reveals NatureKnit, a Patented, Natural Microbiome Ingredient, Exhibits a More Gentle and Significant Prebiotic Effect Compared with Purified FibersNew Study Reveals NatureKnit, a Patented, Natural Microbiome Ingredient, Exhibits a More Gentle and Significant Prebiotic Effect Compared with Purified Fibers

New Study Reveals NatureKnit, a Patented, Natural Microbiome Ingredient, Exhibits a More Gentle and Significant Prebiotic Effect Compared with Purified Fibers

MOMENCE, Ill., March 20, 2025 /PRNewswire/ -- New research published in Microorganisms has revealed the significant impact of NatureKnit™, an all-natural…

1 week ago
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury RecoveryExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery

TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone”…

2 weeks ago
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing RegimenACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious…

3 weeks ago
Orion and Aiforia extend collaboration to preclinical study evaluationsOrion and Aiforia extend collaboration to preclinical study evaluations

Orion and Aiforia extend collaboration to preclinical study evaluations

March 05, 2025 02:00 ET  | Source: Orion Oyj ORION CORPORATION PRESS RELEASE 5 MARCH 2025 at 9.00 EET         …

3 weeks ago
Study finds that 88 per cent of Paris region residents engaged with the GamesStudy finds that 88 per cent of Paris region residents engaged with the Games

Study finds that 88 per cent of Paris region residents engaged with the Games

04 March 2025 - Nearly nine in ten residents of the greater Paris region aged 15 and older – 88 per…

4 weeks ago
Derm-Biomes DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drugDerm-Biomes DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug

Derm-Biomes DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health…

1 month ago
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDIAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target…

1 month ago
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns DiseaseTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET February 22, 2025 02:20 ET  | Source: Teva…

1 month ago
Show more Posts